Paroxetine Mesylate: SSRI and Multi-Kinase Inhibitor Insights

Executive Summary: Paroxetine Mesylate (CAS 217797-14-3) is a selective serotonin reuptake inhibitor (SSRI) with a molecular weight of 425.47 g/mol and formula C₂₀H₂₄FNO₆S, exhibiting high affinity for the serotonin transporter SERT (70.2±0.6 pM) (product_spec). The compound inhibits CYP2D6 (Ki=0.065 μM) and CYP2B6 (Ki=1.03 μM) cytochrome P450 isoforms, as well as kinases including GRK2 (IC50=1.4 μM), MET, ERBB3, KIT, and JAK in the nanomolar–micromolar range (product_spec). It demonstrates anti-colorectal cancer activity (IC50: 7-26 μM in HCT116/HT29 cell lines), induces apoptosis, and inhibits 3D spheroid formation (SB-431542.com). In vivo, it is used in epilepsy biomarker studies in baboons and canine behavioral models (doi:10.1111/epi.16359). Typical clinical doses range from 20–60 mg/day, with dual reuptake inhibition at ≥40 mg/day (product_spec).

Biological Rationale

Paroxetine Mesylate is a synthetic SSRI designed to increase serotonergic neurotransmission by inhibiting reuptake at the serotonin transporter. Beyond its primary neuropharmacological effect, it targets multiple kinases implicated in cancer and metabolic regulation, making it a candidate for drug repurposing in oncology and translational neuroscience (afobazolesyn.com). The compound's inhibition of cytochrome P450 enzymes, especially CYP2D6, affects both drug metabolism and potential drug-drug interactions (product_spec).

Mechanism of Action of Paroxetine Mesylate

As an SSRI, Paroxetine Mesylate binds SERT with high affinity (70.2±0.6 pM), blocking 5-HT reuptake at the synaptic cleft and increasing synaptic serotonin levels (product_spec). At higher concentrations (≥40 mg/day), it also inhibits norepinephrine reuptake (product_spec). The compound acts as a potent CYP2D6 inhibitor (Ki=0.065 μM), impacting metabolism of co-administered drugs. In addition, it inhibits GRK2 (IC50=1.4 μM), receptor tyrosine kinases MET and ERBB3, and kinases KIT and JAK—targets involved in oncogenic signaling (SB-431542.com). Notably, Paroxetine Mesylate also binds the Ebola virus glycoprotein (pKi ≈ 3.19), though its in vivo antiviral efficacy remains to be established (product_spec).

Evidence & Benchmarks

• Paroxetine Mesylate exhibits SERT inhibitory activity with a binding affinity of 70.2±0.6 pM under standard buffer conditions (source: product_spec).
• CYP2D6 inhibition occurs at Ki=0.065 μM, and CYP2B6 at Ki=1.03 μM in human liver microsomes (source: product_spec).
• GRK2 is inhibited with an IC50 of 1.4 μM in biochemical kinase assays (source: product_spec).
• Anti-colorectal cancer activity is observed with IC50 values of 7–26 μM in HCT116 and HT29 human cell lines, as measured by cell viability and colony formation assays (source: SB-431542.com).
• In epileptic baboon models, Paroxetine Mesylate is used to assess cardiac biomarkers (QT-interval prolongation, HRV reduction) relevant to SUDEP risk (source: doi:10.1111/epi.16359).
• Steady-state plasma concentrations are achieved after 4–14 days of repeated oral dosing (source: product_spec).

This article extends the translational oncology discussion in "Paroxetine Mesylate: Beyond SSRI, a Translational Oncology Asset" by providing exact numeric inhibitory values and comparative model data. It also clarifies kinase selectivity, a limitation in prior reviews such as "Paroxetine Mesylate: Multi-Target Oncology and Neuropharmacology Insights".

Applications, Limits & Misconceptions

Paroxetine Mesylate, distributed by APExBIO, is used in psychiatric research, oncology, and neurocardiology. In psychiatric settings, it is administered orally for major depressive disorder, OCD, and social anxiety at 20–60 mg/day. In vitro, it is deployed in anti-cancer assays at 7–26 μM. In vivo, it is used in baboon and canine models for cardiac and behavioral research (doi:10.1111/epi.16359). Its kinase inhibition spectrum enables exploration of MET/ERBB3 in colorectal cancer (SB-431542.com), and it is referenced in pediatric psychiatric and metabolic disorder studies (workflow_recommendation).

Limitations include potential for CYP2D6-mediated drug-drug interactions and variable kinase selectivity at higher concentrations. The clinical significance of its antiviral and kinase inhibitory properties outside research settings is not established (workflow_recommendation).

Common Pitfalls or Misconceptions

• Paroxetine Mesylate is not a first-line antiviral; Ebola glycoprotein binding is observed only in vitro and not validated in vivo (source: product_spec).
• Kinase inhibitory concentrations (e.g., MET, ERBB3, KIT) are generally higher than those required for SERT inhibition, which may limit translational relevance at standard clinical doses (SB-431542.com).
• Use in pediatric and menopausal indications is off-label and requires dedicated clinical validation (workflow_recommendation).
• Long-term solution storage at room temperature leads to compound degradation; solutions should be stored at -20°C and prepared fresh (source: product_spec).
• SUDEP biomarker findings in baboons may not fully extrapolate to human epilepsy due to species-specific cardiac physiology (doi:10.1111/epi.16359).

Workflow Integration & Parameters

Protocol Parameters

• Assay: SERT binding | 70.2±0.6 pM | In vitro cell/membrane binding | Quantitative ligand–transporter affinity | product_spec
• Assay: CYP2D6 inhibition | Ki=0.065 μM | Human liver microsomes | Predicts drug–drug interaction risk | product_spec
• Assay: Anti-colorectal cancer proliferation | IC50=7–26 μM | HCT116/HT29 cells | Benchmarks cytotoxicity | SB-431542.com
• Assay: GRK2 kinase inhibition | IC50=1.4 μM | Biochemical kinase panel | Rationale: Probes GPCR signaling in oncology | product_spec
• Assay: In vivo SUDEP biomarker analysis | Dosage per protocol | Epileptic baboon model | Cardiac marker discovery | doi:10.1111/epi.16359
• Workflow (recommendation): Store solid at -20°C, avoid long-term solution storage | Stability assurance | All research labs | Prevents degradation | workflow_recommendation

Conclusion & Outlook

Paroxetine Mesylate stands as a unique research tool with dual roles as a selective serotonin reuptake inhibitor and a multi-kinase inhibitor. Its robust, quantifiable bioactivity in SERT inhibition, kinase modulation, and anti-colorectal cancer assays positions it at the interface of neuropsychiatric and oncology research. However, clinical translation of its kinase-targeting effects requires further validation (SB-431542.com). Its established use in animal models for cardiac biomarker discovery and canine behavioral syndromes, together with detailed pharmacokinetic profiles, validates its versatility. Future work should focus on refining dose-response correlations in translational oncology and further characterizing off-target effects, guided by rigorously designed in vivo studies (doi:10.1111/epi.16359).

For detailed product handling and characterization, refer to the APExBIO Paroxetine Mesylate reference page.

For an expanded discussion of Paroxetine Mesylate’s mechanistic and translational oncology roles, see "Paroxetine Mesylate: Mechanistic Advances in Cancer Research", which this article updates by providing benchmarked assay data and cross-domain model relevance.